Susan Silbermann
"Susan Silbermann is the Global President for the Emerging Markets in Pfizer's Biopharmaceuticals Group. In this role she manages Pfizer's broad pharmaceuticals portfolio and leads almost 10,000 colleagues across China, Latin America, emerging Asia, Africa and the Middle East. Under her leadership, the Emerging Markets business is innovating to partner with governments, non-governmental organisations, patients and others to increase appropriate access to Pfizer's portfolio in core therapeutic areas including vaccines, medicine for oncology, inflammation and immunology, internal medicine and rare disease. Prior to this role, Susan was the Global President of Pfizer Vaccines responsible for the operational management and commercial development of vaccines that protect people across all stages of life and address unmet needs for serious and life-threatening conditions.
Susan also worked as an advocate to promote the value of vaccination around the world. Ms Silbermann holds a seat on the International Federation of Pharmaceutical Manufacturers & Associations Vaccine CEO Steering Committee. In addition, she serves on the Board of Advisors for Catalyst Inc., a nonprofit organisation that promotes inclusive workplaces for women, and on the Corporate Advisory Board for the Johns Hopkins University Carey Business School (USA). Ms Silbermann has a BSc in Biology and French from Tufts University (USA), and a joint MBA/MA degree in International Business and French studies from the Stern Graduate School of Business (USA) and the Institute of French Studies at New York University (USA)." [1]
- Director, GAVI Alliance
